Open-Label Extension Study to Pioneer Study 6058-SCD-101
Open-Label Extension Study to Pioneer Study 6058-SCD-101
Enrolling by invitation · NCT07401823 · Registry updated 2026-04-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Open-Label Extension Study to Pioneer Study 6058-SCD-101 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease, thalassemia | Enrolling by invitation | Phase 2 | 2026-04-14 | NCT07401823 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fulcrum Therapeutics | 1 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Boston Medical Center | Boston | United States | 200 |
| Inova Schar Cancer Institute | Fairfax | United States | 116 |
| Jacobi Medical Center | The Bronx | United States | 23 |
| Our Lady of The Lake Hospital | Baton Rouge | United States | 6 |
| Queens Hospital Cancer Center | Jamaica | United States | 2 |
| University of Arkansas for Medical Sciences | Little Rock | United States | 218 |
| University of California, Los Angeles | Los Angeles | United States | 142 |
| University of Texas Houston | Houston | United States | 3 |